Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U1 small nuclear 62, pseudogene (RNU1-62P) is a **non-coding RNA pseudogene** related to the U1 small nuclear RNA (snRNA) gene family[1][5]. While canonical U1 snRNAs are essential components of the spliceosome and play critical roles in pre-mRNA splicing, pseudogenes such as RNU1-62P are traditionally classified as nonfunctional genetic elements due to sequence modifications or truncations that prevent their normal function[4]. However, emerging research has shown that some U1 snRNA pseudogenes can be transcribed, processed, and even participate in regulatory functions influencing gene expression in specific cellular contexts[4]. There is no evidence that RNU1-62P acts as a classic drug target (e.g., receptor, enzyme, transporter), nor is it known to interact with therapeutic agents or serve as a biomarker[1][5]. It is not associated with known diseases beyond its annotation as a genomic feature, but variant U1 snRNAs from other loci have been shown to modulate splicing and RNA processing, sometimes in a developmental stage-specific manner[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 62, pseudogene (RNU1-62P).